Great week at #ESMO26 Madrid with my team from #CEMIC @myESMO Now time to head back home!

After a comprehensive review of molecular platforms in early breast cancer, amazing @KalinskyKevin shares their institutional approach 👏👏👏 @myESMO #ESMO26

@AinhoaMada sharing tips for young investigators on how to conduct academic research, at the YO Forum #ESMO26 Ask. Test. Learn. Repeat. #ESMOAmbassadors @myESMO

An amazing pre-day of #ESMO26 Thanks @myESMO for this opportunity to share the Leadership and Career award with inspiring people from all over the word! @AinhoaMada @franclongo @AndresC27622123 @curijoey @FAndreMD

💬 #ESMOconversations: What #ProfessionalAdvice has stayed with you throughout your career? Reflect on those conversations that helped shape your professional path. Share your story to inspire others and tag the people who shaped your #ProfessionalJourney. #ESMO26

Se viene algo nuevo 🔜 ya falta poco

ESMO's new Clinical Trials Funding initiative supports independent academic pragmatic clinical trials to improve #CancerCare and patient outcomes. Open to academic institutions, hospitals, research groups. Application deadline: 1 November 2026 ow.ly/482Q50ZLX3p

Extremely honored to receive @myESMO Leadership and Career Development Award 📃 Together with @SUMAargentina network, we will implement a project focused on pregnancy-associated breast cancer 🤰🏼to provide support to attending physicians 👩‍⚕️and optimize #CancerCare 🦀

🌎 28 recipients. One shared goal: advancing #CancerCare. 🌟 The ESMO Leadership and Career Development Award provides international research opportunities, leadership training and protected project time. 🔗 ow.ly/nxcZ50ZHJcb #ESMOFellowships

👉 By E de Azambuja and N Harbeck, the ESMO Metastatic Breast Cancer Living Guideline provides immediate access to the June 2026 CPG recommendations, with notable systemic treatment updates in several subtypes, in an interactive, mobile-friendly format 🔗 ow.ly/jN5E50ZEoqy

Bases y condiciones: aaoc.org.ar/comite-joven/

Acto inaugural @KowalyszynMD @aaoncoclinica

Arrancando tempranito la Reunion de trabajos y actualización mas importante del año de la Oncología 🇦🇷 en Neuquen!!! @aaoncoclinica La nro 46!!!

#ESMOMembers 📢 Voting for the ESMO President 2029-2030 is open. #ESMOElections An invitation from @FAndreMD to learn more about the candidates and their vision for the Society. Cast your vote 🔗ow.ly/M2Ja50Z4aVW

Back in Berlin this year! Growing year after year. Led by amazing @stolaney1 @myESMO #ESMOBreast26

Weekly #BreastCancer Newsletter- My take of last week’s publications from select high-impact journals (April 13 - April 19, 2026). @OncoDailyBreast @oncodaily #BCSM #BreastCancerResearch #BreastCancer

A recent multicentre study in Lancet Oncology demonstrates that a multimodal deep learning model can predict Oncotype DX recurrence scores directly from H&E histopathology with high accuracy (AUC ~0.90) and consistent external validation across diverse cohorts. • AUC 0.898 for RS ≥26 • r=0.73 vs genomic score • External AUC 0.86–0.90 • HR 2.6–2.9 for recurrence endpoints Overall, this work represents a significant step toward integrating digital pathology and AI into therapeutic decision-making in breast cancer. Prospective trials are required before clinical implementation. @dviramar2 @TheLancetOncol @OncoAlert 👉 thelancet.com/journals/lanon…

40 years ago, a young physician submitted a paper reporting on the alteration of a gene called HER2/neu to Science. He didn’t know that it was the beginning of one of the most remarkable scientific stories of the human kind, which would eventually impact the lives of COUNTLESS patients with cancer — first via mABs, then through ADCs, bsAbs and beyond. Unforgettable Keynote presentation by Dennis Slamon at #MBCC26.

Do you have an impactful research idea? One that could improve patient care or advance scientific excellence? Apply for the ESMO Leadership & Career Development Award, offering protected research time, leadership & communication training by 3 May 26 🔗ow.ly/F4NM50Yqc9w #Oncology #ESMOYOC @TeresaSAmaral  @E_de_Azambuja  @DrAngelaLamarca @Rodrosb

New Real-Life Evidence on Adjuvant CDK4/6 Inhibitors in Colombia - Alfredo Sebastián Golemba @PabloMando oncodaily.com/voices/alfredo… #OncoDaily #Oncology #Cancer #Health #Medicine #MedX